Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03369223 · ClinicalTrials.gov registry record · Phase 1
A Study of BMS-986249 Alone and in Combination With Nivolumab in Advanced Solid Tumors
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 356
- Enrollment target
NCT03369223 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 356 participants.
The verdict
NCT03369223, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 356 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether BMS-986249 both by itself and in combination with Nivolumab is safe and tolerable in the treatment of advanced solid tumors
Interventions
- BIOLOGICAL Nivolumab
- BIOLOGICAL Ipilimumab
- BIOLOGICAL BMS-986249
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 356 participants |
| Start Date | 2017-12-06 |
| Est. Completion | 2024-11-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03369223
The ClinicalTrials.gov registry entry for NCT03369223 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 356 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Nivolumab is the first listed.
NCT03369223 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03369223 about?
NCT03369223 is a clinical study titled "A Study of BMS-986249 Alone and in Combination With Nivolumab in Advanced Solid Tumors". The purpose of this study is to determine whether BMS-986249 both by itself and in combination with Nivolumab is safe and tolerable in the treatment of advanced solid tumors
What is the current status of trial NCT03369223?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 356 participants. The study started on 2017-12-06. Estimated completion is 2024-11-07.
What interventions are being tested in trial NCT03369223?
The interventions under investigation include: Nivolumab (BIOLOGICAL), Ipilimumab (BIOLOGICAL), BMS-986249 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03369223?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.